Figure 2. miR-503-5p inhibits proliferation, migration, and angiogenic abilities of HCAECs while promoting the proliferation and migration of HCASMCs. HCAECs and HCASMCs were treated with exogenous miR-503-5p mimic (with miR-mimic NC as a control) or exogenous miR-503-5p inhibitor (with miR-inhibitor NC as a control). (A) The expression of miR-503-5p (normalized to U6) in HCAECs and HCASMCs determined by RT-qPCR. (B) The proliferation of HCAECs and HCASMCs detected by CCK-8 assay. (C) The migration of HCAECs detected by transwell migration assays and scratch test. (D) Vessel-like tubes formed in HCAECs detected by Matrigel-based angiogenesis assays. (E) Apoptosis of HCAECs detected by flow cytometry. (F) The migration of HCASMCs detected by transwell migration assays and scratch test. Values obtained from three independent experiments in triplicate were analyzed by one-way ANOVA followed by Tukey's post hoc test among three or more groups. *p < 0.05 compared with HCAECs or HCASMCs treated with miR-mimic NC; *p < 0.05 compared with HCAECs or HCASMCs treated with miR-inhibitor NC.